A Phase I/Ib Dose Escalation Trial of Futibatinib in Combination With Paclitaxel/Ramucirumab in Second Line Confirmed Locally Advanced/Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

This study is testing a new combination of three different cancer medications to see if they are safe and effective for treating certain types of stomach or esophageal cancer that cannot be removed by surgery. Researchers hope that by using these drugs together, they can better block the signals and blood supply that cancer cells need to grow and spread.

This study is for adults with stomach, esophageal, or gastroesophageal junction cancer that is advanced or cannot be removed by surgery. Participants must meet specific criteria, such as having certain genetic markers and having received only one prior treatment for their cancer.

If you join, you will receive a combination of the study medications and will be closely monitored by the medical team. You will also have regular check-ups, which include blood tests and imaging scans like CT or MRI scans to keep track of how your body and your cancer are responding.

The study is taking place in Chicago, Illinois, and Columbus, Ohio. It is currently in the planning stages and is not yet open for new participants.